NCI Protocol #: CITN-04 Version Date: 27 Jan 2016 1 NCI Protocol #: CITN-04 Local Protocol #: CITN-04 TITLE: A Phase II Pilot Trial of an Indol eamine2,3, dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients with Advanced Melanoma (Advanced Melanoma – ICD-10053571) Coordinating Center: Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center *Principal Investigator: Craig Slingluff, Jr., M.D. University of Virginia 434-924-1730 434-243-6844 Cls8h@virginia.edu Co-Investigators: Mark S.